摘要
目的评价比阿培南与亚胺培南西司他丁钠治疗重症肺炎的成本-效果。方法将40例重症肺炎患者随机分为比阿培南组(18例)和亚胺培南西司他丁钠组(22例)进行治疗,采用药物经济学原理对两种治疗方案进行成本-效果分析。结果比阿培南组和亚胺培南西司他丁钠组治疗重症肺炎的有效率分别为94.44%和90.91%(P>0.05);成本-效果比(C/E)分别为66.01和113.58。结论比阿培南组的成本-效果比优于亚胺培南西司他丁钠组,比阿培南治疗重症肺炎有明显的药物经济学优势。
Objective To evaluate the cost-effectiveness of biapenem and imipenem-cilastatin injections in the treatment of severe pneumonia,in order to provide rational use of the drugs,and lower the treatment cost.Methods Forty patients with severe pneumonia were randomly divided into biapenem group（n=18） and imipenem-cilastatin group（n=22）.Principle of pharmacoeconomics was adopted to analyze cost-effectiveness of the two treatment schemes.Results The effective rates of biapenem and imipenem-cilastatin group in the treatment of severe pneumonia were 94.44% and 90.91% respectively（P0.05）.The cost-effectiveness ratio（C/E） were 66.01 and 113.58 respectively. Conclusion Cost-effectiveness ratio of biapenem superior to that of imipenem-cilastatin,and biapenem has marked pharmacoeconomics advantage over imipenem-cilastatin for severe pneumonia.
出处
《临床医学》
CAS
2012年第2期5-7,共3页
Clinical Medicine
